Free Writing Prospectus dated November 19, 2024
Relating to Prospectus dated November 19, 2024
Filed Pursuant to Rule 433 under the Securities Act of 1933
Registration Statement No. 333-283339
QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group
SAN DIEGO, CA, November 19, 2024 – QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”),
a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch
of an underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company’s common stock (“Common Stock”).
The Selling Stockholder will receive all of the proceeds from the Offering. The Company is not selling any shares of Common Stock in the Offering and will not
receive any proceeds from the Offering.
The last reported sale price of QuidelOrtho’s Common Stock on November 19, 2024 was $38.58 per share.
Goldman Sachs & Co. LLC is acting as the sole underwriter of the Offering.
The underwriter proposes to offer the shares of Common Stock to the public
at a fixed price, which may be changed at any time without notice.
Following the Offering, the Selling Stockholder will not beneficially own any shares
of QuidelOrtho’s Common Stock, other than de minimis amounts held or owned from time to time in the ordinary course of business. As a result, QuidelOrtho’s Principal Stockholders Agreement with the Selling Stockholder will terminate
pursuant to its terms and the Selling Stockholder will no longer have the right to nominate members to QuidelOrtho’s Board of Directors in accordance with the terms of the Principal Stockholders Agreement.
The Offering is being made pursuant to an effective shelf registration statement (including a prospectus) filed by the Company with the U.S. Securities and
Exchange Commission (“SEC”) to which this communication relates. Before you invest, you should read the prospectus in the shelf registration statement and other documents the Company has filed with the SEC for more complete information
about the Company and the Offering. The Offering will be made only by means of a free writing prospectus, a prospectus and a related prospectus supplement relating to the Offering, copies of which may be obtained from Goldman Sachs & Co.
LLC, Attention: Prospectus Department, 200 West Street, New York, NY, 10282, phone number: (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com. A copy of the free writing prospectus, the
prospectus and the related prospectus supplement relating to the Offering may also be obtained free of charge by visiting EDGAR on the SEC’s website at www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Cautionary Note Concerning Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are any statement contained herein that is not strictly historical, including, but not limited to, statements
regarding the expected sale of Common Stock by the Selling Stockholder in the Offering. Without limiting the foregoing, the words “may,” “will,” “would,” “should,” “might,” “expect,”
“anticipate,” “believe,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” “continue” or similar words, expressions or the
negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho’s